Resumen

OCHOA MONTES, Luis A.  y  FERRER MARRERO, Daisy. Cardiovascular injury in COVID-19: An extension of pulmonary disease. CorSalud [online]. 2021, vol.13, n.1, pp. 68-85.  Epub 01-Mar-2021. ISSN 2078-7170.

Faced with a pneumonia outbreak in 59 suspected patients at a local seafood market in Wuhan, China, the first case of a novel coronavirus was laboratory-confirmed on December 1, 2019. On January 7, 2020, a new type of virus of the family Coronaviridae called SARS-CoV-2 -causative agent of COVID-19- was identified. The few initial reports restricted involvement to the lower respiratory tract. Both, disease progression and build-up of scientific evidence, proved the crucial role played by cardiovascular involvement in the development and prognosis of the infection. Age is an independent predictor of mortality and an association between pre-existing cardiovascular disease and severe forms of the disease has been demonstrated. Cardiovascular involvement may be either direct or indirect; acute myocardial injury, myocarditis, acute myocardial infarction, heart failure, arrhythmias and venous embolic events stand out among others. Adverse effects of treatment for cardiac complications and drug testing in therapeutic protocols may be contributing aspects. This paper addresses cardiovascular involvement due to COVID-19.

Palabras clave : SARS-CoV-2; COVID-19; Cardiovascular complications; Risk factors; Mortality.

        · resumen en Español     · texto en Español     · Español ( pdf ) | Inglés ( pdf )